Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer.

Sun JM, Rampal S, Lee G, Lee J, Choi YL, Parasuraman B, Guallar E, Cho J, Shim YM.

Lung Cancer. 2013 May;80(2):191-6. doi: 10.1016/j.lungcan.2013.01.009. Epub 2013 Feb 4.

PMID:
23384673
2.

[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].

Li J, Qu L, Wei X, Gao H, Wang W, Qin H, Tang C, Guo W, Wang H, Liu X.

Zhongguo Fei Ai Za Zhi. 2012 May;15(5):299-304. doi: 10.3779/j.issn.1009-3419.2012.05.09. Chinese.

3.

Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC.

Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z, Minarik M.

Neoplasma. 2013;60(4):425-31. doi: 10.4149/neo_2013_055.

PMID:
23581415
4.

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.

Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.

Clin Cancer Res. 2012 Aug 15;18(16):4406-14. doi: 10.1158/1078-0432.CCR-12-0357. Epub 2012 Jun 25.

5.

[Association between different EGFR mutation status and survival in pemetrexed-based chemotherapy for advanced non-small cell lung cancer].

Jia B, He XH, Yang S, Wang ZP, Li JL, Wang Y, Wang HY, Xing PY, Liu YT, Shi YK.

Zhonghua Yi Xue Za Zhi. 2013 Dec;93(46):3659-62. Chinese.

PMID:
24534344
6.

Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.

Uramoto H, Yamada T, Yano S, Kondo N, Hasegawa S, Tanaka F.

Anticancer Res. 2012 Sep;32(9):3785-90.

PMID:
22993320
7.

Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations.

Yoshida K, Yatabe Y, Park J, Ogawa S, Park JY, Shimizu J, Horio Y, Matsuo K, Mitsudomi T, Hida T.

J Cancer Res Clin Oncol. 2010 Apr;136(4):527-35. doi: 10.1007/s00432-009-0685-2. Epub 2009 Sep 24.

PMID:
19777258
8.

Treatment outcomes in elderly with advanced-stage non-small cell lung cancer.

Tam TC, Ho JC, Wong MK, Wong WM, Wang JK, Lam JC, Lui MM, Lam WK, Ip MS, Lam DC.

Lung. 2013 Dec;191(6):645-54. doi: 10.1007/s00408-013-9498-9. Epub 2013 Aug 9.

9.

The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.

Wu WS, Chen YM, Tsai CM, Shih JF, Lee YC, Perng RP, Whang-Peng J.

J Chin Med Assoc. 2013 Dec;76(12):682-5. doi: 10.1016/j.jcma.2013.08.006. Epub 2013 Sep 21.

10.

EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital.

Choi YL, Sun JM, Cho J, Rampal S, Han J, Parasuraman B, Guallar E, Lee G, Lee J, Shim YM.

PLoS One. 2013;8(2):e56011. doi: 10.1371/journal.pone.0056011. Epub 2013 Feb 28.

11.

[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].

Fan Y, Huang ZY, Yu HF, Luo LH.

Zhonghua Zhong Liu Za Zhi. 2010 Nov;32(11):859-63. Chinese.

PMID:
21223694
12.

A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.

Kawahara A, Taira T, Azuma K, Tominaga M, Hattori S, Kawahara M, Abe H, Yamaguchi T, Akiba J, Takamori S, Hayashi A, Kage M.

Lung Cancer. 2012 Oct;78(1):39-44. doi: 10.1016/j.lungcan.2012.07.002. Epub 2012 Jul 31.

PMID:
22858448
13.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.

J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472.

PMID:
18458038
14.

Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.

Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, Yang XN, An SJ, Wang BC, Huang YS, Wang Z, Wu YL.

J Clin Oncol. 2011 Aug 20;29(24):3316-21. doi: 10.1200/JCO.2010.33.3757. Epub 2011 Jul 25.

PMID:
21788562
16.

EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.

Faehling M, Eckert R, Kamp T, Kuom S, Griese U, Sträter J, Ott G, Spengler W.

Lung Cancer. 2013 Jun;80(3):306-12. doi: 10.1016/j.lungcan.2013.02.010. Epub 2013 Mar 11.

PMID:
23489557
17.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.

Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR.

Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12. Review.

19.

EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer.

Wang Z, Zhang X, Bai H, Zhao J, Zhuo M, An T, Duan J, Yang L, Wu M, Wang S, Wang Y, Wu Y, Wang J.

Oncology. 2012;83(5):248-56. doi: 10.1159/000341381. Epub 2012 Sep 4.

PMID:
22964709
20.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.

Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Kim CS, Heo DS, Bang YJ.

Lung Cancer. 2009 Jul;65(1):80-4. doi: 10.1016/j.lungcan.2008.10.016. Epub 2008 Dec 6.

PMID:
19059670

Supplemental Content

Support Center